A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?
Q2
A home drug screening test kit is currently being developed. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How might the sensitivity and specificity of the test change if the cut-off level is changed to 2 mg/uL?
Q3
You are developing a new diagnostic test to identify patients with disease X. Of 100 patients tested with the gold standard test, 10% tested positive. Of those that tested positive, the experimental test was positive for 90% of those patients. The specificity of the experimental test is 20%. What is the positive predictive value of this new test?
Q4
A family doctor in a rural area is treating a patient for dyspepsia. The patient had chronic heartburn and abdominal pain for the last 2 months and peptic ulcer disease due to a suspected H. pylori infection. For reasons relating to affordability and accessibility, the doctor decides to perform a diagnostic test in the office that is less invasive and more convenient. Which of the following is the most likely test used?
Q5
You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?
Q6
A 28-year-old woman dies shortly after receiving a blood transfusion. Autopsy reveals widespread intravascular hemolysis and acute renal failure. Investigation reveals that she received type A blood, but her medical record indicates she was type O. In a malpractice lawsuit, which of the following elements must be proven?
Q7
A 32-year-old woman presented for her annual physical examination. She mentioned that her family history had changed since her last visit: her mother was recently diagnosed with breast cancer and her sister tested positive for the BRCA2 mutation. The patient, therefore, requested testing as well. If the patient tests positive for the BRCA1 or BRCA2 mutation, which of the following is the best screening approach?
Q8
The World Health Organization suggests the use of a new rapid diagnostic test for the diagnosis of malaria in resource-limited settings. The new test has a sensitivity of 70% and a specificity of 90% compared to the gold standard test (blood smear). The validity of the new test is evaluated at a satellite health center by testing 200 patients with a positive blood smear and 150 patients with a negative blood smear. How many of the tested individuals are expected to have a false negative result?
Q9
A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?
Q10
A 28-year-old male presents to his primary care physician with complaints of intermittent abdominal pain and alternating bouts of constipation and diarrhea. His medical chart is not significant for any past medical problems or prior surgeries. He is not prescribed any current medications. Which of the following questions would be the most useful next question in eliciting further history from this patient?
Serial vs parallel testing US Medical PG Practice Questions and MCQs
Question 1: A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?
A. 82%
B. 90%
C. 84%
D. 86%
E. 98% (Correct Answer)
Explanation: ***98%***
- **Specificity** measures the proportion of **true negatives** among all actual negatives.
- In this case, 800 patients are known to be EBV-free (actual negatives), and 20 of them tested positive (false positives). This means 800 - 20 = 780 tested negative (true negatives). Specificity = (780 / 800) * 100% = **98%**.
*82%*
- This value represents the *original sensitivity* before the scientist’s new attempts to improve the test.
- It does not reflect the *newly calculated specificity* based on the provided data.
*90%*
- This value represents the *newly calculated sensitivity* of the test, not the specificity.
- Out of 1200 EBV-infected patients, 120 tested negative (false negatives), meaning 1080 tested positive (true positives). Sensitivity = (1080 / 1200) * 100% = 90%.
*84%*
- This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results.
- It does not correspond to any of the calculated values for the new test's performance.
*86%*
- This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results.
- It does not correspond to any of the calculated values for the new test's performance.
Question 2: A home drug screening test kit is currently being developed. The cut-off level is initially set at 4 mg/uL, which is associated with a sensitivity of 92% and a specificity of 97%. How might the sensitivity and specificity of the test change if the cut-off level is changed to 2 mg/uL?
A. Sensitivity = 92%, specificity = 97%
B. Sensitivity = 95%, specificity = 98%
C. Sensitivity = 100%, specificity = 97%
D. Sensitivity = 90%, specificity = 99%
E. Sensitivity = 97%, specificity = 96% (Correct Answer)
Explanation: ***Sensitivity = 97%, specificity = 96%***
- Lowering the cut-off from 4 mg/uL to 2 mg/uL means that more individuals will be classified as **positive** (anyone with drug levels ≥2 mg/uL instead of ≥4 mg/uL). This change will **increase the sensitivity** (capturing more true positives, fewer false negatives) but **decrease the specificity** (more false positives among those without the condition).
- Therefore, sensitivity will increase (e.g., to 97%), and specificity will decrease (e.g., to 96%), reflecting the fundamental trade-off between these metrics.
*Sensitivity = 92%, specificity = 97%*
- This option reflects the **original values** at the 4 mg/uL cut-off and does not account for the change in the threshold.
- A change in the cut-off level will inherently alter the test's performance characteristics.
*Sensitivity = 95%, specificity = 98%*
- This option suggests an increase in **both sensitivity and specificity**, which is generally not possible by simply changing the cut-off level in the same direction.
- There is typically an **inverse relationship** between sensitivity and specificity when adjusting the cut-off threshold.
*Sensitivity = 100%, specificity = 97%*
- Reaching **100% sensitivity** while maintaining a high specificity is highly unlikely with a simple cut-off adjustment.
- While sensitivity would increase with a lower cut-off, achieving perfect sensitivity is unrealistic in clinical practice.
*Sensitivity = 90%, specificity = 99%*
- This option suggests a **decrease in sensitivity** and an **increase in specificity**.
- A lower cut-off would lead to more positive results, thus increasing sensitivity and reducing specificity, which contradicts the proposed values.
Question 3: You are developing a new diagnostic test to identify patients with disease X. Of 100 patients tested with the gold standard test, 10% tested positive. Of those that tested positive, the experimental test was positive for 90% of those patients. The specificity of the experimental test is 20%. What is the positive predictive value of this new test?
A. 10%
B. 90%
C. 95%
D. 11% (Correct Answer)
E. 20%
Explanation: ***11%***
- The positive predictive value (PPV) is calculated as **true positives / (true positives + false positives)**.
- From 100 patients, 10 have disease (prevalence 10%). With 90% sensitivity, the test correctly identifies **9 true positives** (90% of 10).
- Of 90 patients without disease, specificity of 20% means 20% are correctly identified as negative (18 true negatives), so **72 false positives** = 90 × (1 - 0.20).
- Therefore, PPV = 9 / (9 + 72) = 9/81 = **11.1% ≈ 11%**.
*10%*
- This value represents the **prevalence** of the disease in the population, not the positive predictive value of the test.
- Prevalence is the proportion of individuals who have the disease (10 out of 100 patients).
*90%*
- This figure represents the **sensitivity** of the test, which is the percentage of true positives correctly identified by the experimental test.
- Sensitivity = true positives / (true positives + false negatives) = 9/10 = 90%.
*95%*
- This value is not directly derivable from the given data and does not represent any standard test characteristic in this context.
- It would imply a much higher PPV than what can be calculated given the low specificity of 20%.
*20%*
- This is the stated **specificity** of the test, which measures the proportion of true negatives correctly identified.
- Specificity = true negatives / (true negatives + false positives) = 18/90 = 20%.
Question 4: A family doctor in a rural area is treating a patient for dyspepsia. The patient had chronic heartburn and abdominal pain for the last 2 months and peptic ulcer disease due to a suspected H. pylori infection. For reasons relating to affordability and accessibility, the doctor decides to perform a diagnostic test in the office that is less invasive and more convenient. Which of the following is the most likely test used?
A. Steiner's stain
B. Culture of organisms from gastric specimen
C. Stool antigen test (Correct Answer)
D. Detection of the breakdown products of urea in biopsy
E. Serology (ELISA testing)
Explanation: ***Stool antigen test***
- This **non-invasive** and **cost-effective** test detects *H. pylori* antigens in stool, making it suitable for a rural setting with limited resources.
- It is highly sensitive and specific, useful for both initial diagnosis and confirming eradication after treatment.
*Steiner's stain*
- **Steiner's stain** (Steiner silver stain) is primarily used for histological visualization of *Legionella* species, and **not for** *H. pylori* detection in routine clinical practice.
- It requires an **endoscopic biopsy**, making it more invasive and costly than the stool antigen test.
*Culture of organisms from gastric specimen*
- This method requires an **endoscopic biopsy** and specialized culture facilities, which may not be available in a rural doctor's office.
- It is more expensive and time-consuming, and primarily used when **antibiotic resistance** is suspected.
*Detection of the breakdown products of urea in biopsy*
- This refers to the **rapid urease test** (e.g., CLOtest), which is performed on a **gastric biopsy** obtained during endoscopy.
- While quick, it is an **invasive procedure** requiring endoscopy, which contradicts the patient's and doctor's preferences for a less invasive test.
*Serology (ELISA testing)*
- **Serology** detects antibodies to *H. pylori* but cannot differentiate between **active infection** and **past exposure**.
- Its utility in monitoring eradication is limited, and it's generally not recommended as the primary diagnostic test due to its inability to confirm active infection.
Question 5: You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?
A. 450 / (450 + 10)
B. 490 / (10 + 490)
C. 490 / (50 + 490)
D. 450 / (450 + 50) (Correct Answer)
E. 490 / (450 + 490)
Explanation: ***450 / (450 + 50)***
- **Sensitivity** is defined as the proportion of actual positive cases that are correctly identified by the test.
- In this study, there are **500 patients with colon cancer** (actual positives), and **450 of them tested positive** for the marker, while **50 tested negative** (500 - 450 = 50). Therefore, sensitivity = 450 / (450 + 50) = 450/500 = 0.9 or 90%.
*450 / (450 + 10)*
- This formula represents **Positive Predictive Value (PPV)**, which is the probability that a person with a positive test result actually has the disease.
- It incorrectly uses the total number of **test positives** in the denominator (450 true positives + 10 false positives) instead of the total number of diseased individuals, which is needed for sensitivity.
*490 / (10 + 490)*
- This is actually the correct formula for **specificity**, not sensitivity.
- Specificity = TN / (FP + TN) = 490 / (10 + 490) = 490/500 = 0.98 or 98%, which measures the proportion of actual negative cases correctly identified.
- The question asks for sensitivity, not specificity.
*490 / (50 + 490)*
- This formula incorrectly mixes **true negatives (490)** with **false negatives (50)** in an attempt to calculate specificity.
- The correct specificity formula should use false positives (10), not false negatives (50), in the denominator: 490 / (10 + 490).
*490 / (450 + 490)*
- This calculation incorrectly combines **true negatives (490)** and **true positives (450)** in the denominator, which does not correspond to any standard epidemiological measure.
- Neither sensitivity nor specificity uses both true positives and true negatives in the denominator.
Question 6: A 28-year-old woman dies shortly after receiving a blood transfusion. Autopsy reveals widespread intravascular hemolysis and acute renal failure. Investigation reveals that she received type A blood, but her medical record indicates she was type O. In a malpractice lawsuit, which of the following elements must be proven?
A. Duty, breach, causation, and damages (Correct Answer)
B. Only duty and breach
C. Only breach and causation
D. Duty, breach, and damages
Explanation: ***Duty, breach, causation, and damages***
- In a medical malpractice lawsuit, all four elements—**duty, breach, causation, and damages**—must be proven for a successful claim.
- The healthcare provider had a **duty** to provide competent care, they **breached** that duty by administering the wrong blood type, this breach **caused** the patient's death and renal failure, and these injuries constitute **damages**.
*Only duty and breach*
- While **duty** and **breach** are necessary components, proving only these two is insufficient for a malpractice claim.
- It must also be demonstrated that the breach directly led to the patient's harm and resulted in legally recognized damages.
*Only breach and causation*
- This option omits the crucial elements of professional **duty** owed to the patient and the resulting **damages**.
- A claim cannot succeed without establishing that a duty existed and that quantifiable harm occurred.
*Duty, breach, and damages*
- This option misses the critical element of **causation**, which links the provider's breach of duty to the patient's injuries.
- Without proving that the breach *caused* the damages, even if a duty was owed and breached, and damages occurred, the claim would fail.
Question 7: A 32-year-old woman presented for her annual physical examination. She mentioned that her family history had changed since her last visit: her mother was recently diagnosed with breast cancer and her sister tested positive for the BRCA2 mutation. The patient, therefore, requested testing as well. If the patient tests positive for the BRCA1 or BRCA2 mutation, which of the following is the best screening approach?
A. Order magnetic resonance imaging of the breast
B. Annual ultrasound, annual mammography, and monthly self-breast exams
C. Twice-yearly clinical breast exams, annual mammography, annual breast MRI, and breast self-exams (Correct Answer)
D. Annual clinical breast exams, annual mammography, and monthly self-breast exams
E. Refer to radiation therapy
Explanation: ***Twice-yearly clinical breast exams, annual mammography, annual breast MRI, and breast self-exams***
- For patients with **BRCA1 or BRCA2 mutations**, an intensive breast cancer screening protocol is recommended due to their highly increased lifetime risk of breast cancer.
- This typically includes **semiannual clinical breast exams**, **annual mammography**, and **annual breast MRI**, often starting at a young age.
*Order magnetic resonance imaging of the breast*
- While MRI is a crucial part of screening for high-risk individuals, it is **not sufficient as a standalone screening modality**.
- A comprehensive approach combining multiple screening methods is needed to maximize detection rates.
*Annual ultrasound, annual mammography, and monthly self-breast exams*
- **Breast ultrasound** is generally used as an adjunct to mammography when specific abnormalities are found or in women with dense breasts, not as a routine primary screening tool for BRCA carriers.
- While **mammography** and **self-breast exams** are included, this option lacks the crucial **annual MRI** and **twice-yearly clinical breast exams** recommended for BRCA carriers.
*Annual clinical breast exams, annual mammography, and monthly self-breast exams*
- This protocol is **less intensive** than what is recommended for women with BRCA mutations.
- It omits the essential **annual breast MRI** and the **twice-yearly clinical breast exams** that are critical for early detection in this high-risk population.
*Refer to radiation therapy*
- **Radiation therapy** is a treatment modality for existing cancer, not a screening approach for cancer prevention or early detection.
- Referring for radiation therapy would be appropriate only after a diagnosis of breast cancer, not as a primary screening strategy.
Question 8: The World Health Organization suggests the use of a new rapid diagnostic test for the diagnosis of malaria in resource-limited settings. The new test has a sensitivity of 70% and a specificity of 90% compared to the gold standard test (blood smear). The validity of the new test is evaluated at a satellite health center by testing 200 patients with a positive blood smear and 150 patients with a negative blood smear. How many of the tested individuals are expected to have a false negative result?
A. 60 (Correct Answer)
B. 15
C. 135
D. 155
E. 195
Explanation: ***Correct Option: 60***
- **False negatives** occur in individuals who have the disease but test negative. This is directly related to the test's **sensitivity**.
- Given a sensitivity of 70%, 30% of actual positive cases (100% - 70%) will be missed. With 200 patients having a positive blood smear (meaning they have malaria), 30% of 200 is 0.30 × 200 = **60**.
*Incorrect Option: 15*
- This number represents the expected number of **false positives** (150 patients without disease × 10% false positive rate = 15).
- However, the question asks for **false negatives**, not false positives.
*Incorrect Option: 135*
- This value represents the number of **true negatives** (150 patients without malaria × 90% specificity = 135).
- It does not represent false negative results.
*Incorrect Option: 155*
- This appears to be a distractor number that doesn't correspond to any standard diagnostic test calculation in this scenario.
- It does not represent false negatives or any meaningful combination of the given parameters.
*Incorrect Option: 195*
- This number might be derived from incorrectly applying formulas or miscalculating the relationship between sensitivity and false negatives.
- It does not represent the correct calculation for false negatives.
Question 9: A 65-year-old non-smoking woman with no symptoms comes to your clinic to establish care with a primary care provider. She hasn’t seen a doctor in 12 years and states that she feels very healthy. You realize that guidelines by the national cancer organization suggest that she is due for some cancer screening tests, including a mammogram for breast cancer, a colonoscopy for colon cancer, and a pap smear for cervical cancer. These three screening tests are most likely to be considered which of the following?
A. Tertiary prevention
B. Primary prevention
C. Secondary prevention (Correct Answer)
D. Cancer screening does not fit into these categories
E. Quaternary prevention
Explanation: ***Secondary prevention***
- **Secondary prevention** aims to detect and treat a disease early, before symptoms appear, to prevent its progression or recurrence.
- **Cancer screening tests** such as mammograms, colonoscopies, and Pap smears fit this category perfectly as they are performed in asymptomatic individuals to identify early-stage cancer or pre-cancerous lesions.
*Tertiary prevention*
- **Tertiary prevention** focuses on minimizing the impact of an established disease and improving quality of life through treatment and rehabilitation.
- This would involve managing existing cancer, not screening for it.
*Primary prevention*
- **Primary prevention** aims to prevent a disease from occurring in the first place, often through health promotion and risk reduction.
- Examples include vaccination, lifestyle modifications (e.g., healthy diet, exercise), or avoiding smoking.
*Cancer screening does not fit into these categories*
- This statement is incorrect as cancer screening is a well-established component of preventive healthcare.
- It clearly falls within the defined categories of prevention, specifically secondary prevention.
*Quaternary prevention*
- **Quaternary prevention** aims to protect patients from medical interventions that are likely to cause more harm than good, or to avoid over-medicalization.
- This concept is distinct from screening for diseases and focuses on ethical considerations in medical care.
Question 10: A 28-year-old male presents to his primary care physician with complaints of intermittent abdominal pain and alternating bouts of constipation and diarrhea. His medical chart is not significant for any past medical problems or prior surgeries. He is not prescribed any current medications. Which of the following questions would be the most useful next question in eliciting further history from this patient?
A. "Does the diarrhea typically precede the constipation, or vice-versa?"
B. "Is the diarrhea foul-smelling?"
C. "Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life"
D. "Are the symptoms worse in the morning or at night?"
E. "Can you tell me more about the symptoms you have been experiencing?" (Correct Answer)
Explanation: ***Can you tell me more about the symptoms you have been experiencing?***
- This **open-ended question** encourages the patient to provide a **comprehensive narrative** of their symptoms, including details about onset, frequency, duration, alleviating/aggravating factors, and associated symptoms, which is crucial for diagnosis.
- In a patient presenting with vague, intermittent symptoms like alternating constipation and diarrhea, allowing them to elaborate freely can reveal important clues that might not be captured by more targeted questions.
*Does the diarrhea typically precede the constipation, or vice-versa?*
- While knowing the sequence of symptoms can be helpful in understanding the **pattern of bowel dysfunction**, it is a very specific question that might overlook other important aspects of the patient's experience.
- It prematurely narrows the focus without first obtaining a broad understanding of the patient's overall symptomatic picture.
*Is the diarrhea foul-smelling?*
- Foul-smelling diarrhea can indicate **malabsorption** or **bacterial overgrowth**, which are important to consider in some gastrointestinal conditions.
- However, this is a **specific symptom inquiry** that should follow a more general exploration of the patient's symptoms, as it may not be relevant if other crucial details are missed.
*Please rate your abdominal pain on a scale of 1-10, with 10 being the worst pain of your life*
- Quantifying pain intensity is useful for assessing the **severity of discomfort** and monitoring changes over time.
- However, for a patient with intermittent rather than acute, severe pain, understanding the **character, location, and triggers** of the pain is often more diagnostically valuable than just a numerical rating initially.
*Are the symptoms worse in the morning or at night?*
- Diurnal variation can be relevant in certain conditions, such as inflammatory bowel diseases where nocturnal symptoms might be more concerning, or functional disorders whose symptoms might be stress-related.
- This is another **specific question** that should come after gathering a more complete initial picture of the patient's symptoms to ensure no key information is overlooked.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
